The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Search for "alendronate"

Search results for: alendronate

Osteoporosis Experts Discuss Bisphosphonate Holidays

November 24, 2020 • By Susan Bernstein

ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday?… [Read More]

Filed Under: ACR Convergence, Conditions, Meeting Reports Tagged With: ACR Convergence 2020, Bisphosphonate, bone mineral density (BMD), drug holiday, Fractures, Osteoporosis

New Findings on Hydroxychloroquine, Denosumab

November 12, 2020 • By Ruth Jessen Hickman, MD

ACR Convergence 2020—At two plenary sessions, speakers highlighted key findings, including results on the QTc interval in patients on hydroxychloroquine, and data from a study on denosumab vs. alendronate for glucocorticoid-induced osteoporosis. The QTc Interval & Hydroxychloroquine The safety profile and optimal dosing of hydroxychloroquine has been a topic for decades because it is known… [Read More]

Filed Under: ACR Convergence, Conditions, Drug Updates, Meeting Reports, Rheumatoid Arthritis Tagged With: ACR Convergence 2020, bone mineral density (BMD), COVID-19, denosumab, Fractures, Hydroxychloroquine (HCQ), Osteoporosis

Bisphosphonates Reduce Bone Toughness Over Time

August 11, 2020 • By Will Boggs, MD

NEW YORK (Reuters Health)—Using bisphosphonates for several years is associated with increasing brittleness and decreasing toughness of bone, according to a new review. “Long-term treatment with bisphosphonates can have negative side effects in some people because of their effects on bone toughness [toughness = the energy that bone tissue can absorb before cracking],” David B…. [Read More]

Filed Under: Drug Updates Tagged With: bisphosphonates, bone, bone mineral density (BMD), Fractures, Osteoporosis, osteoporosis treatments

In Memoriam … J. Timothy Harrington, MD, MACR: July 6, 1940–June 23, 2020

June 30, 2020 • By William Arnold, MD; Tim Bartholow, MD; Drew Johnson, MS, MBA; Joel Kremer, MD; Daniel Malone, MD; Eric D. Newman, MD; Kenneth Saag, MD; & Douglas White, MD

June saw the passing of a beloved colleague, mentor and friend to many in the rheumatology community when J. Timothy Harrington, MD, died of pancreatic cancer in his hometown of Madison, Wis. Dr. Harrington trained at Massachusetts General Hospital, the National Institutes of Health National Cancer Institute and UT Southwestern Medical Center, and served on… [Read More]

Filed Under: Professional Topics, Profiles Tagged With: Dr. J. Timothy Harrington, Harrington

Zoledronate After Denosumab Does Not Fully Prevent Bone Loss

June 23, 2020 • By Marilynn Larkin

NEW YORK (Reuters Health)—In postmenopausal women and men treated for at least two years with denosumab, a single infusion of zoledronate given after denosumab discontinuation does not completely prevent bone turnover and loss, researchers say. Given the findings, “bone mineral density (BMD) should probably be higher than the current target for discontinuation of bisphosphonate treatment… [Read More]

Filed Under: Conditions Tagged With: bone loss, bone mineral density (BMD), denosumab, Osteoporosis, osteoporosis treatments, zoledronate

After Hip Fracture, Earlier Osteoporosis Drug Initiation Tied to Lower Subsequent Fracture Risk

June 15, 2020 • By Lisa Rapaport

(Reuters Health)—Patients hospitalized for a hip fracture are less likely to experience a subsequent fracture-related hospitalization if they start anti-osteoporosis medication sooner, a Taiwanese study suggests.1 Researchers examined data on 77,930 patients aged 50 years and older hospitalized for hip fractures, including 9,986 people prescribed anti-osteoporosis medications within one year of the index fracture. Compared… [Read More]

Filed Under: Uncategorized Tagged With: drug treatment, Fractures, Osteoporosis, osteoporosis treatments

Osteoporosis Experts Discuss Bisphosphonates, Chronic Kidney Disease

March 19, 2019 • By Lara C. Pullen, PhD

CHICAGO—The osteoporosis session at the 2018 ACR/ARHP Annual Meeting opened with a discussion by Kenneth Saag, MD, MSc, professor of medicine at the University of Alabama, Birmingham, in which he highlighted adverse events associated with osteoporosis medications. Dr. Saag began his presentation by emphasizing that, above all, the audience should keep in mind that the… [Read More]

Filed Under: Conditions, Meeting Reports Tagged With: 2018 ACR/ARHP Annual Meeting, Association of Rheumatology Professionals (ARP), Bisphosphonate, chronic kidney disease, Osteoporosis

FDA Advisory Committee Votes in Favor of Romosozumab Approval

January 30, 2019 • By Michele B. Kaufman, PharmD, BCGP

An FDA advisory committee voted 18-1 in favor of approving romosozumab to treat postmenopausal women with osteoporosis.... [Read More]

Filed Under: Drug Updates Tagged With: bone, FDA, Osteoporosis, romosozumab, U.S. Food and Drug Administration (FDA)

A Balancing Act: Tips to Ensure Optimal Screening & Treatment for Osteoporosis

November 12, 2018 • By Carina Stanton

Patients with rheumatic diseases may be undertreated for osteoporosis. To decrease fracture risk for at-risk patients, rheumatologists can engage patients in shared decision making with regular screening and education about treatment options…... [Read More]

Filed Under: Conditions Tagged With: bone, fracture risk, Fractures, Osteoporosis, patient care

Improve Your Recognition & Treatment of Osteoporosis

July 19, 2018 • By Jason Liebowitz, MD

BALTIMORE—Rheumatologists may not think about osteoporosis on a daily basis, but they should, said Dr. Karl Insogna, the Ensign Professor of Medicine at Yale University School of Medicine and director of the Yale Bone Center in New Haven, Conn., in his recent lecture at the Maryland Society for the Rheumatic Diseases. With approximately 75 million… [Read More]

Filed Under: Conditions Tagged With: alendronate, bisphosphonates, corticosteroids, denosumab, Osteoporosis, raloxifene, risedronate, teriparatide, zoledronic acid

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 8
  • Next Page »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)